Novartis Lauds Long-Term Benefits Of Leqvio At ESC
LDL-C Levels Reduced By 50%
Executive Summary
Putting aside access issues for Leqvio, Novartis has presented data showing that the small interfering RNA directed PCSK9 twice-a-year injection provides consistent low-density lipoprotein cholesterol reduction over six years and more.
You may also be interested in...
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
What Verona Needs To Make COPD Drug Ensifentrine A Success
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.